Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non–Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508)

Jyoti D. Patel, Ju Whei Lee, David P. Carbone, Henry Wagner, Anil Shanker, Maria Teresa P. de Aquino, Leora Horn, Melissa L. Johnson, David E. Gerber, Jane Jijun Liu, Millie S. Das, Mohammed Ali Al-Nsour, Christopher S.R. Dakhil, Suresh Ramalingam, Joan H. Schiller

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Fingerprint

Dive into the research topics of 'Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non–Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508)'. Together they form a unique fingerprint.

Medicine & Life Sciences